Skip to main content

Advertisement

Table 2 Immunological laboratory examinations

From: Clinical study of children with cryofibrinogenemia: a retrospective study from a single center

Case 1 2 3 4 5 6 7 8 No. Positive/No. All checked (%)
Cryofibrinogen (+) (+) (+) (+) (+) (+) (+) (+) 8/8 (100)
Cryoglobulin (+) (−) (−) (−) (−) (−) (−) (−) 0/8 (0)
α1-antitrypsin ND ND (−) ND ND (−) ND (−) 0/3 (0)
PT/aPTT(initial) (−) (−) (−) (−) (−) (−) (−) (−) 0/8 (0)
Bleeding time (−) ND ND ND ND ND ND ND 0/1 (0)
IgA (−) (−) (−) (−) (−) (−) ND (−) 0/7 (0)
Platelet count (−) (−) (−) (−) (−) (−) (−) (−) 0/7 (0)
vWF ND (−) I (−) (−) I (−) (−) 2/7 (28.5)
C3 (−) D (−) (−) D (−) D D 4/8 (50)
C4 (−) (−) (−) D (−) D I D 4/8 (50)
Protein C I (−) (−) I I (−) I I 5/8 (62.5)
Protein S I (−) D D D D D I 7/8 (87.5)
Anti-thrombin III I I I I I I I I 8/8 (100)
Lupus anticoagulant (−) ND (+) (−) (+) (−) (−) (−) 2/7 (28.5)
RA factor (−) (−) (+) (−) (−) (+) (−) (+) 3/8 (37.5)
Antinuclear Factor (−) (−) (−) (−) (−) (−) (−) (+) 1/8 (12.5)
Anti-cardiolipin IgG (−) (−) (−) (−) (+) (−) (−) (−) 1/8 (12.5)
Anti-cardiolipin IgM (−) (−) (−) (−) (+) (−) (−) (−) 1/8 (12.5)
anti-ENA (all) (−) (−) (−) (−) (+) (−) (−) (−) 1/8 (12.5)
Anti CCP ND ND ND (−) (−) (−) (−) (−) 0/5 (0)
ANCA-C (−) (−) ND ND (−) (−) (−) (−) 0/6 (0)
ANCA-P (−) (−) ND ND (−) (−) (−) (−) 0/6 (0)
Anti-β2 GP1 IgG (−) (−) (−) (−) (−) (−) (−) (−) 0/8 (0)
Anti-β2 GP1 IgM (−) (−) (−) (−) (−) (−) (−) (−) 0/8 (0)
Anti-ds DNA (−) (−) (−) (−) (−) (−) (−) (−) 0/8 (0)
Anti-SSA (−) (−) (−) (−) (−) (−) (−) (−) 0/8 (0)
Anti-SSB (−) (−) (−) (−) (−) (−) (−) (−) 0/8 (0)
  1. CCP cyclic citrullinated peptide, ANCA-C cytoplasmic anti-neutrophil cytoplasmic antibody, ANCA-P peri-nuclear anti-neutrophil cytoplasmic antibody, Anti-β2 GP1 Anti-β2-glycoprotein I, ENA extractable nucleic antigen, SSA Sjögren’s-syndrome-related antigen-A, Anti-SSB Sjögren’s-syndrome-related antigen-B